European (ethnic group)

Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Global Markets

2 weeks ago talkbio0Tagged Amgen settlement, Biocon Biologics, Biosimilars, biosimilars approval, bone health, Commission, denosumab, entry - ActRelationshipCheckpoint, Europe market, European (ethnic group), Evfraxy, Neoplasms, Vevzuo

Biocon Biologics; Denosumab biosimilars; Vevzuo; Evfraxy; Europe market entry; Amgen settlement; biosimilars approval; European Commission; bone health; oncology

MediView Achieves First CE Mark, Bringing Augmented Reality to European Healthcare

2 weeks ago talkbio0Tagged augmented, Augmented Reality, CE Mark, clinical visualization, European (ethnic group), GE HealthCare, Health care facility, Interventional radiology, MediView, MediView XR, MediView XR90, reality

MediView; CE Mark; augmented reality; European healthcare; mixed reality; clinical visualization; MediView XR; MediView XR90; GE Healthcare; interventional radiology

Cytek Biosciences Deepens Commitment to Expanding Access to Flow Cytometry

2 months ago talkbio0Tagged Amsterdam facility, Awards, cell analysis, Collaboration, Cytek Biosciences, European (ethnic group), expansion, Flow Cytometry, FSP, Instrument - device, ISAC, Research Projects, R-Series, Spectrum Profiling

Cytek Biosciences; flow cytometry; access expansion; ISAC collaboration; instrument awards; research grants; Full Spectrum Profiling (FSP); European expansion; Amsterdam facility; cell analysis

Trump’s Pharmaceutical Tariffs Materialize in New US-EU Trade Deal

5 months ago talkbio0Tagged 15%, European (ethnic group), Evaluation, pharmaceutical tariffs, Sectioning technique, tariff, trade agreement, Transplant Registry Unified Management Program, U.S., Union, US-EU

Trump; pharmaceutical tariffs; US-EU trade deal; 15% tariff; Section 232 investigation; European Union exports; trade agreement

Biotech Restructuring and European Regulatory Setbacks

9 months ago talkbio0Tagged Commission, European (ethnic group), factor IX, LifeMine, Muscular Dystrophy, Duchenne, regulatory, Translarna

LifeMine Therapeutics, layoffs, PTC Therapeutics, Translarna, Duchenne muscular dystrophy, European Commission, regulatory decision

Gilead’s Seladelpar Receives Conditional EU Approval for Primary Biliary Cholangitis Treatment

10 months ago talkbio0Tagged Biliary Cholangitis, Commission, Conditional, European (ethnic group), Gilead Sciences, Primary Biliary Cholangitis, Response process, seladelpar, ursodiol

Seladelpar, Gilead Sciences, primary biliary cholangitis, PBC, European Commission, conditional marketing authorization, RESPONSE trial, ursodeoxycholic acid (UDCA)